Cited by 342Cancer-related Molecular PathwaysTelomeres, Telomerase, and SenescenceMicrotubule and mitosis dynamics

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

The Requirement for Cyclin D Function in Tumor Maintenance

Open access

Choi, Yoon Jong, Li, Xiaoyu, Hydbring, Per, Sanda, Takaomi, Stefano, Joanna, Christie, Amanda L., Signoretti, Sabina, Look, A. Thomas, Kung, Andrew L., von Boehmer, Harald, Sicinski, Piotr·2012·Cancer Cell

DOI 10.1016/j.ccr.2012.09.015PMC PMC3487466

Open this paper in CoChat — free account Open PDF

Abstract

D-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer treatment, we engineered mouse strains that allow acute and global ablation of individual D-cyclins in a living animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D-associated kinase activity in mice bearing ErbB2-driven mammary carcinomas triggered tumor cell senescence, without compromising the animals' health. Ablation of cyclin D3 in mice bearing Notch1-driven T cell acute lymphoblastic leukemias (T-ALL) triggered tumor cell apoptosis. Such selective killing of leukemic cells can also be achieved by inhibiting cyclin D associated kinase activity in mouse and human T-ALL models. Inhibition of cyclin D-kinase activity represents a highly-selective anticancer strategy that specifically targets cancer cells without significantly affecting normal tissues.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2012.09.015

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citation
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“CyclinCDK complexes phosphorylate cellular proteins, thereby driving cell cycle progression (Malumbres and Barbacid, 2009).”
Background
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Self-citation
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“Hypophosphorylated (active) pRB protein was shown to enforce the senescent state by permanently silencing expression of E2F target genes, such as cyclin E1, cyclin A2 or Dhfr (Chicas et al., 2010; Narita et al., 2003; Dean et al., 2010).”
Background
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Efficient Recombination in Diverse Tissues by a Tamoxifen-Inducible Form of Cre: A Tool for Temporally Regulated Gene Activation/Inactivation in the Mouse
Hayashi, S., & McMahon, A. P. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0597 · Cited by 1,351
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
Muller, W., Sinn, E., Pattengale, P., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,246
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“As soon as breast tumors were detected, we started treating mice with PD 0332991, a specific and potent inhibitor of cyclin D-CDK4 and D-CDK6 kinases (Fry et al., 2004).”
Background

Flagged first, then by citations

Show all 56 references

Sorted by citations

Items 301–341 of 341

Kinases in motion: impact of protein and small molecule interactions on kinase conformationsPreprint
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · eLife · doi:10.7554/elife.94755.2 · Cited by 1
DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradationPreprint
Zheng, R., Prasad, A., Satyabola, D., Xu, Y., & Yan, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613743 · Cited by 1
Cyclin D1 regulates the hepatic response to feeding: Evidence for non-cell cycle roles in the liverPreprint
Wu, H., Hauser, J. I., Yang, N., Timchenko, N., Klaers, M., Salekeen, R., Manivel, J. C., Abrahante, J. E., Laux, L., Yousefzadeh, M. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727739 · Cited by 1
Explore Rb/E2F Activation Dynamics to Define the Control Logic of Cell Cycle Entry in Single Cells
Dong, P. (2015) · DukeSpace (Duke University) · doi:10.13140/rg.2.1.5168.8720 · Cited by 1
COMMIPHORA MUKUL EXTRACT AND GUGGULSTERONE EXHIBIT ANTITUMOUR ACTIVITY THROUGH INHIBITION OF CYCLIN D1, NF-Κß AND INDUCTION OF APOPTOSIS IN ORAL CANCER CELLS
Bharti, V., Gupta, U. D., & Das, S. N. (2015) · Asian Journal of Pharmaceutical and Clinical Research
OPINION The current therapeutic scenario for relapsed mantle cell lymphoma
Ferrero, S., & Dreyling, M. H. (2013)
Anti-tumour effects of resveratrol and pterostilbene on ovarian cancer.
Hosking, J. (2016) · UC Research Repository (University of Canterbury) · doi:10.26021/6023
The role of CDK inhibitors in breast cancer therapy
Huszno, J. (2016) · University of Texas Health Sciences Center San Antonio - International Journal of Cancer Therapy and Oncology · doi:10.14319/ijcto.43.4
Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis
Guo, Y., Liang, Z., Hou, X., & Zhang, Z. L. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7176
The Role of Zyxin and LIMD1 in Mitosis and Cancer
Zhou, J. (2019) · DigitalCommons@UNMC
A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) ProgramPreprint
Thavaneswaran, S., Sebastian, L. T., Kansara, M., Ballinger, M. L., Espinoza, D., Lin, F., Lee, C. K., Sjoquist, K. M., Grady, J. P., Cowley, M. J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-254137/v1
New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia
Raikar, S. S., Teachey, D. T., & Gossai, N. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-85147-7_14
Faculty Opinions recommendation of The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Skotheim, J. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727689917.793545777
Targeting a vicious cycle
(2012) · Nature · doi:10.1038/490449b
Faculty Opinions recommendation of CDK4/6 inhibition triggers anti-tumour immunity.
El‐Deiry, W. S., Sikder, R. K., & Lulla, A. R. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.728653214.793537665
Faculty Opinions recommendation of PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.
Riedel, R. F. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733284124.793580992
Data from Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Rampal, R. K., Pinzon-Ortiz, M. C., Somasundara, A. V. H., Durham, B. H., Koche, R. P., Spitzer, B. G., Mowla, S., Krishnan, A., Li, B., An, W., et al. (2023) · doi:10.1158/1078-0432.c.6530277
Data from Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms
Rampal, R. K., Pinzon-Ortiz, M. C., Somasundara, A. V. H., Durham, B. H., Koche, R. P., Spitzer, B. G., Mowla, S., Krishnan, A., Li, B., An, W., et al. (2023) · doi:10.1158/1078-0432.c.6530277.v1
Application of epigenetic therapies in combination with cyclin dependent kinase inhibitors (CDKIs) in patients with metastatic breast cancer to reverse tumor resistance: two case reports
Nezami, M. A., Hager, S. J., & Aryan Chaychian, B. S. (2023) · MOJ Biology and Medicine · doi:10.15406/mojbm.2023.08.00202
Kinases in motion: impact of protein and small molecule interactions on kinase conformationsPreprint
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.11.575270
Kinases in motion: impact of protein and small molecule interactions on kinase conformationsPreprint
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · eLife · doi:10.7554/elife.94755.1
Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report
Cai, Y., Zhang, J., Duan, H., & Liu, F. (2025) · Oncology Letters · doi:10.3892/ol.2025.14973
CDKN1A (p21 Cip/Waf1 ) stabilizes Cyclin D3 by inhibiting its phosphorylation-dependent nuclear export following butyrate treatmentPreprint
Ghrib, M. A., Dayhoff, G. W., Chahtour, C., Rodrigues, C. M., Youssef, A., Schillaci, G., Gautreau, G., Henry, C., Uversky, V. N., Rigolet, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.19.660543
CDK4/6 inhibitors for the treatment of breast cancer
Ayush, S., Snehal, P., Singh, R. M., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33653-9.00008-9
Additional file 10 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561060
Additional file 1 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561033
Additional file 4 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561042
Additional file 3 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561039
Additional file 6 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561048
Additional file 5 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561045
Additional file 8 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561054
Additional file 7 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561051
Additional file 1 of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor
Tatum, J. L., Kalen, J. D., Jacobs, P. M., Riffle, L. A., James, A., Thang, L., Sanders, C., Hollingshead, M. G., Basuli, F., Shi, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20517125
Additional file 9 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561057
Additional file 2 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561036
Additional file 11 of On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561063
Stabilization of cyclin D3 protein by CDKN1A (p21Cip/Waf1) in butyrate-treated cells
Ghrib, M. A., Dayhoff, G. W., Chahtour, C., Rodrigues, C. M., Youssef, A., Schillaci, G., Gautreau, G., Henry, C., Uversky, V. N., Rigolet, P., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02767-6
Functional analysis of the proliferation antigen, KI-67 roles in cancer
Mrouj, K. (2018) · HAL · doi:10.70675/66203ba0zb848z43f0za8d6zcda2bc074cbc
Mechanisms of cell cycle regulation by CDK4 / 6 and pathways for the formation of resistance to their inhibitors (literature review)
Kutsebko, D. N., & Glushakov, R. I. (2026) · Malignant tumours · doi:10.18027/2224-5057-2026-067
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
Dernovšek, J., Cingl, J., Fonović, U. P., & Tomašič, T. (2026) · Medicinal Research Reviews · doi:10.1002/med.70079
From challenge to solution: Perspectives on AI-powered multi-omics in tackling CDK4/6 inhibitor resistance in breast cancer
Wu, J., Liu, X., & Wu, G. (2026) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2026.09.001

Authors: Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., & Sicinski, P.
Affiliations: Harvard University (US)
Boston Children's Hospital (US)
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
ORCID: Choi, Yoon Jong
Li, Xiaoyu
Hydbring, Per
Sanda, Takaomi
Signoretti, Sabina
Look, A. Thomas
Kung, Andrew L.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2012-10
Volume: 22
Issue: 4
Pages: 438-451
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2012.09.015
PMC: PMC3487466
OpenAlex: W2126821691
Cited by: 342
References: 56
Citations by year: 2026: 10 · 2025: 14 · 2024: 23 · 2023: 27 · 2022: 30 · 2021: 20 · 2020: 31 · 2019: 29 · 2018: 32 · 2017: 36 · 2016: 24 · 2015: 19 · 2014: 27 · 2013: 17 · 2012: 3
FWCI: 10.45
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 380 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (P01 CA080111, P01 CA109901, R01 CA083688)
National Cancer Institute (1K99CA157951)
Novartis
Children’s Leukemia Research Association
Japan Society for the Promotion of Science
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
Keywords: cyclin D1, cyclin D3, tumor maintenance, cell cycle, tumor cell senescence, apoptosis, breast cancer, targeted cancer therapy
MeSH terms: Animals, Female, Humans, Mammary Neoplasms, Experimental, Neoplasms, Apoptosis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cyclin-Dependent Kinase 4, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Requirement for Cyclin D Function in Tumor Maintenance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks